Richard Klein to Sphingolipids
This is a "connection" page, showing publications Richard Klein has written about Sphingolipids.
Connection Strength
0.668
-
Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins. J Clin Lipidol. 2022 Mar-Apr; 16(2):173-183.
Score: 0.153
-
Transcriptomics Reveal Altered Metabolic and Signaling Pathways in Podocytes Exposed to C16 Ceramide-Enriched Lipoproteins. Genes (Basel). 2020 02 07; 11(2).
Score: 0.134
-
Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes. J Clin Lipidol. 2019 May - Jun; 13(3):481-491.e1.
Score: 0.126
-
Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism. 2014 Oct; 63(10):1287-95.
Score: 0.091
-
Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res. 2010 Oct; 51(10):3074-87.
Score: 0.069
-
HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate. J Lipid Res. 2010 Sep; 51(9):2619-28.
Score: 0.068
-
Increased Plasma Levels of Select Deoxy-ceramide and Ceramide Species are Associated with Increased Odds of Diabetic Neuropathy in Type 1 Diabetes: A Pilot Study. Neuromolecular Med. 2017 Mar; 19(1):46-56.
Score: 0.026